Abstract: Introduction: Heparin is known to efficiently attenuate metastasis in various tumour models by different mechanisms including inhibition of tumour cell contacts with soluble and cellular components such as inhibition of heparanase or P-and L-selectin. We recently showed that heparin efficiently binds to VLA-4 integrin in melanoma cells in vitro. Here we describe VLA-4 integrin as a mediator of melanoma metastasis that is inhibited by the low molecular weight heparin (LMWH) Tinzaparin. Materials and Methods: sh-RNA-mediated knock-down of VLA-4 integrin in B16F10 murine melanoma cells (B16F10-VLA-4kd) was performed and cell binding characteristics were investigated in vitro. Experimental metastasis of B16F10-VLA-4kd and B16F10 cells and interference by Tinzaparin were analysed in mice. Results: VLA-4 knock-down of B16F10 cells resulted in loss of VCAM-1 binding, but preserved the capacity to bind platelets through P-selectin. The observed reduced metastasis of B16F10-VLA-4kd cells confirmed the role of VLA-4 in this process. However, loss of melanoma VLA-4 function hardly further affected reduction of metastasis in P-selectin deficient mice. Tinzaparin treatment of mice injected with B16F10 and B16F10-VLA-4kd cells significantly reduced metastasis suggesting its potential to block both P-and L-selectin and VLA-4 in vivo. The use of N-acetylated heparin, which has no VLA-4 binding activity but blocks P-and L-selectin was less efficient than Tinzaparin in mice injected with B16F10 cells and B16F10-VLA-4kd cells. Conclusion: These findings provide evidence that heparin inhibits experimental melanoma metastasis primarily by blocking VLA-4 and P-selectin.
INTRODUCTION
The metastatic spread of solid tumours is the major cause for the poor outcome of cancer patients. The settlement of tumour cells in distant organs is commonly described as a metastatic cascade. Tumour cells detach from the primary tumour, migrate through the extracellular matrix, invade the blood circulation, interact with blood constituents, adhere to the endothelium, extravasate, and proliferate in distant tissues. Adhesion molecules mediate the critical interaction between tumour cells and the vascular endothelium as well as cellular and soluble blood components.
The selectin family of vascular adhesion receptors has early been identified as key players in the metastatic process [1] [2] [3] . In the early phase of hematogenous metastasis P-selectin expressed on activated platelets and endothelium contributes to platelet-rich tumour cell emboli formation resulting in protection of tumour cells from innate immune system [4, 5] . Lselectin expressed by leukocytes facilitates the interaction of the tumour microemboli with the endothelium [6, 7] .
Integrins are a larger family of adhesion receptors that facilitate the interaction of tumour cells with vasculature and circulating cells in the metastatic course. However, the exact role of integrins in this process remains under investigation. One member of this family is the very late activation antigen-4 (VLA-4, α 4 β 1 ) expressed under physiological conditions on different subtypes of leukocytes, but is also found on melanoma, osteosarcoma, and rhabdomyosarcoma cells [8] [9] [10] [11] . VLA-4 is able to bind to its ligand vascular cell adhesion molecule-1 (VCAM-1) expressed by activated endothelium thereby mediating adhesion and a subsequent transmigration of tumour cells [8, 12] . Accordingly, VLA-4 contribution to metastasis has been demonstrated in several studies [13] [14] [15] . In addition, the enhanced expression of VLA-4 on melanomas correlates with poor clinical outcome [16] [17] [18] . A lot of efforts have been invested into inhibition of adhesion receptors of the selectin or integrin family and thereby intervention in metastasis [19] .
Heparin is routinely administered to cancer patients for an antithrombotic prophylaxis due to their increased risk for cancer-associated thrombosis. In a series of prospective clinical trials heparin has been shown to prolong survival of cancer patients especially those with initial better prognosis [20] [21] [22] [23] [24] . These effects were shown not only to be dependent on the antithrombotic properties of heparin, but on the capacity to reduce metastasis by inhibition of P-and L-selectin [25, 26] . In addition, several other anti-metastatic activities of heparin have been described including (i) inhibition of angiogenesis via stimulation of tissue factor pathway inhibitor (TFPI) release from the endothelium [27] , (ii) modification of growth factors and chemokines binding to their receptors [28] , (iii) inhibition of tumour cell secreted heparanase [29] , (iv) potential interference with chemoresistance of cancer cells [30] .
Furthermore, LMWH is apparently affecting intracellular signaling to downregulate the expression of FAK/p53 and PKCα which gave rise to a decrease in cell-substratum interface area, an alleviated melanoma cell migration, and an altered cell morphology [31, 32] .
Earlier we demonstrated that heparin also binds to the integrin VLA-4 on melanoma cells and impedes the interaction with its endothelial ligand VCAM-1 in vitro. We performed several structure-activity correlations for several non-anticoagulant heparin derivatives based on chain length and sulfation degree [33] . Particularly, a N-acetylated heparin derivative was completely incapable to inhibit the VLA-4 adhesion but binds P-and L-selectin [33] .
However, a LMWH such as Tinzaparin, appears most suitable to cover the anti-adhesive activities that is in line with the other anti-metastatic activities including anticoagulative effects.
Although the role of VLA-4 in melanoma metastasis has been approached before [12] [13] [14] [15] , the potential of heparin to inhibit metastasis through blocking VLA-4 interactions has not been explored until now. In the present study we demonstrate for the first time that heparin interference with VLA-4 reduces the metastatic dissemination of melanoma cells. Inhibition with LMWH Tinzaparin or a non-VLA-4 binding heparin derivative provides evidence that the VLA-4 inhibition is critical for attenuation of experimental melanoma metastasis.
MATERIALS and METHODS

Chemicals and proteins
Recombinant human VCAM-1-Fc chimera, anti-human P-selectin mAb, control mAb, antimouse integrin CD49d mAb (Phycoerythrin (PE)-labeled), and thrombin receptor activator peptide 6 (TRAP-6) were purchased from R&D Systems (Wiesbaden-Nordenstadt, Germany).
Tinzaparin was obtained from LEO Pharma GmbH (Neu-Isenburg, Germany). Bovine serum albumin (BSA), sepharose ® 4B, and cyanuric chloride were from Sigma-Aldrich (Deisenhofen, Germany), and Calcein-AM from Molecular Probes Europe BV (Leiden, Netherlands). The Nacetylated heparin derivatives were prepared as previously described [34] .
Cell culture
The 
Platelet isolation and cell platelet interaction
Blood was collected from healthy volunteers in 15 mL tubes containing 1.6 mg potassium EDTA/mL blood. Afterwards, blood was centrifuged at 200 g for 20 min at 20°C to gain platelet-rich plasma. Separation of platelets from plasma proteins was conducted by gel filtration through a sepharose ® 4B column. For adhesion experiments and for viability determination, platelets were labeled with 5 μg/5 mL Calcein-AM for 30 min at 37°C. 
Transmigration of B16F10
Migration assays were performed in a 96 well transwell containing 8 μm pore-size inserts 
Flow chamber assay
The interaction of B16F10 and B16F10-VLA-4kd cells with the ligand VCAM-1 was investigated under physiological flow conditions in a parallel plate flow chamber as described before [35, 36] . Briefly, VCAM-1 Fc chimera (0.2 μg) was coated on glass slides which were incorporated into a parallel plate flow chamber and mounted on an inverted microscope. Animal experiments
) in a C57BL/6J background and control wild-type (wt) C57BL/6J mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA).
C57BL/6J or P-sel -/-mice were intravenously injected with 67 IU of Tinzaparin or 150 µg of N- 
Statistics
Data are represented as mean ± standard deviation of at least three independent experiments. Comparisons were performed by the unpaired Student´s t-test.
RESULTS
Impact of VLA-4 on B16F10 cell adhesion in vitro and transmigration
To investigate the relevance of VLA-4 for metastatic dissemination of tumour cells we chose the highly metastatic murine melanoma cell line B16F10 that constitutively expresses VLA-4.
B16F10 cells strongly adhered to immobilized VCAM-1 under physiological flow conditions [35] . Using shRNA approach we prepared VLA-4 knock-down cells, B16F10-VLA-4kd, which displayed a VLA-4 downregulation of up to 40 % compared to the wild type cells as determined by flow cytometry (Fig. 1A) . B16F10 cells transfected with a control plasmid (B16F10 control cells) as expected had no effect. In a first step the binding of B16F10 cells to a bEnd.3 endothelial layer was analysed under static conditions (Fig. 1C) . Both, VLA-4 and P-selectin contribute to endothelial interaction of the B16F10 cells, which was confirmed by application of mAbs against VLA-4 and P-selectin. Although VLA-4 on B16F10 cells can efficiently be blocked by Tinzaparin, it has to compete with high affinity P-selectin ligands on B16F10 cell for P-selectin binding on endothelial cells.
Therefore a complete P-selectin inhibition is not ensured, as clearly evident in case of the B16F10-VLA-4-kd cells.
To simulate further steps in the metastatic process, we tested the transmigration efficiency of B16-VLA-4kd through endothelial cells (Fig. 1D) . The B16F10-VLA-4-kd displayed a reduced transmigration rate (0.67 +/-0.02) compared with B16F10 cells (1.0 +/-0.1), which indicates the importance of VLA-4 for both, contact formation and transmigration.
Next we asked whether the VLA-4 downregulation has any impact on the selectin binding of B16F10-VLA-4kd clone cells. P-selectin and L-selectin were previously shown to facilitate metastasis of melanomas [29] . Therefore, we analysed the interaction of activated, P-selectin expressing platelets with B16F10 and B16F10-VLA-4kd clone cells (Fig. 2) . First we analysed the platelet-melanoma interactions under static conditions using fluorescence microscopy ( Fig. 2A ) Taken together, the tumour cell-platelet interaction is P-selectin mediated, sensitive to Tinzaparin and not affected by VLA-4 downregulation. Thus, we confirmed that the B16F10-VLA-4kd cells are suitable to differentiate between VLA-4-dependent and P-selectindependent binding which will enable us to study the inhibitory potential of heparin in vivo.
VLA-4 mediates experimental metastasis of B16F10
To evaluate the involvement of VLA-4 on B16F10 during hematogenous metastasis, we intravenously injected C57BL/J6 mice with 1.5×10 5 B16F10, B16F10-VLA-4kd cells, or B16F10 control cells, respectively. Mice were terminated after 14 days and the number of pulmonary metastatic nodules was determined (Fig. 3) . While mice injected with B16F10 or B16F10 control cells showed almost displaced lungs with metastasis, injection of B16F10-VLA-4kd cells resulted in a significant reduction of metastatic foci. These results clearly confirm VLA-4 as a key player in experimental B16F10 melanoma metastasis.
Differentiation between P-selectin and VLA-4-mediated melanoma metastasis
There is a large body of evidence that P-selectin and L-selectin facilitate metastasis of tumour cells when they are still in the circulation [4, 6] . Therefore, we aimed to differentiate between the contribution of tumour cell-derived VLA-4 and selectin ligands to metastasis of B16F10 melanoma. We injected B16F10 or B16F10-VLA-4kd cells to P-selectin deficient mice. We observed significant attenuation of metastasis with both cells indicating that in the absence of P-selectin, VLA-4 presence or absence did not have a statistically significant effect on the reduced number of metastatic nodules (Fig. 4) .
Tinzaparin as an inhibitor of P-selectin and VLA-4-mediated interactions
Next we assessed the anti-metastatic activity of heparin with the aim to compare VLA-4 inhibition to P-selectin inhibition. We recently provided evidence that LMWH Tinzaparin has a high affinity binding to P-selectin and VLA-4 in the low micromolar range [33] .
We injected wild type mice with 67 IU of Tinzaparin 10 min prior to injection of B16F10 or B16F10-VLA-4kd cells. Tinzaparin treatment of mice almost abolished experimental metastasis of B16F10 and B16F10-VLA-4kd cells (Fig. 5 ). Next we injected P-selectin deficient mice with Tinzaparin prior to application of B16F10 or B16F10-VLA-4kd cells (Fig 4) .
Tinzaparin treatment further reduced metastasis to background levels indicating that other biological activities beyond adhesion (e.g. coagulation) are also part of antimetastatic treatment.
To further dissect the role of VLA-4 and P-selectin inhibition during metastatic seeding, we tested a N-acetylated heparin derivative, which failed to bind to VLA-4, but preserves P-and L-selectin binding capacity [29, 33] . N-acetylated heparin treatment of mice injected with B16F10 cells was less efficient than Tinzaparin which emphasizes a metastasis-contributing role of melanoma derived VLA-4, as indicated in Fig.3 . In addition, N-acetylated heparin treatment of mice injected with B16F10-VLA-4kd cells resulted in a further but not significant reduction of metastatic burden, however not to the level reached by Tinzaparin treatment.
Together, these findings provided evidence that inhibition of P-selectin is the major anti-metastatic activity of Tinzaparin, while inhibition of VLA-4-mediated interactions further blocks metastatic spread.
DISCUSSION
The anti-metastatic activities of heparin have been a matter of intensive research during the last decade and research on therapeutic potential is still ongoing. Several molecular mechanisms of heparin have been described and also have been experimentally confirmed.
Inhibition of coagulation seems to be a basis for heparin activities, also in blocking metastasis. Despite a great variation in the tested tumour models, the blockade of P-and Lselectin appears also as an important target of heparin [25] . This opinion further underlined the importance of cellular adhesion receptors in the metastatic cascade and their role as therapeutic targets.
Compared to selectins, the receptor family of integrins is ubiquitously expressed by virtually all cells, and different integrin pairs are involved in variety of cellular processes [38] . However their role during cancer metastasis is less defined and studied.
Here we studied the role of VLA-4 integrin in melanoma metastasis and evaluated the inhibitory potential of heparin. Several melanoma cells express high levels of the integrin VLA-4 on their surfaces [11] . The relevance of VLA-4 interaction with VCAM-1 on the endothelium during metastatic spread has been shown by several groups in the early 90s [13] [14] [15] . Accordingly, VLA-4 was proposed as a target for interference in the metastatic cascade. Nevertheless, VLA-4 has attracted more attention as a target for autoimmune diseases like multiple sclerosis, where a blocking antibody has been approved for therapy [39] .
Recently we provided evidence for a heparin capacity to bind VLA-4 [35] . Although we described numerous structure-activity relationships of heparin-VLA-4 binding [36] the relevance of this interaction has never been addressed in vivo. Here we show that VLA-4 on murine melanoma cell line B16F10 contributes dominantly to its experimental metastasis.
Furthermore, we provide evidence for the first time that a LMWH -Tinzaparin -blocks VLA-4 in vivo thereby reducing the metastatic dissemination of melanoma cells. Although these findings have been conducted in an experimental metastasis assay, certain effects of metastasis formation (an impact of microenvironment) are not adequately reflected, these data allude to a novel physiologically relevant mechanism how heparin interferes with experimental metastasis. However, we acknowledge that a spontaneous metastasis model would be more relevant to the clinical setting.
We show that integrin and P-selectin are two adhesion mechanisms involved in metastatic spread. Our results indicate that in the P-sel -/-background, VLA-4 only has a minimal and not significant additional contribution to the establishment of metastatic foci and that P-selectin is dominant over the integrin VLA-4 which was also confirmed under in vitro conditions.
VLA-4 mediates endothelial arrest of melanoma cells that is supported by P-selectinmediated tumour cell emboli formation. Interestingly, Tinzaparin almost completely attenuates metastasis of both wt B16F10 and B16F10-VLA-4kd cells. This is in agreement with the capacity of Tinzaparin to affect both P-selectin and VLA-4 binding. However, Nacetylated heparin has only capacity to bind P-selectin but not VLA-4 and is nonanticoagulant [33] . Accordingly, N-acetylated heparin attenuated metastasis of B16F10 cells less efficiently compared to Tinzaparin. Nevertheless a significant decrease in the number of metastatic foci was observed in mice injected with B16F10-VLA-4kd cells and treated with Nacetylated heparin blocking P-selectin compared to non-treated controls. These results indicate that both P-selectin and VLA-4 mediated interactions significantly contribute to metastatic spread of melanoma cells.
Tinzaparin treatment almost completely inhibited metastasis, indicating additional biological activity beyond inhibition of cell adhesion. Tumor-induced coagulation has a significant role in thrombus formation that is associated with cancer progression [40, 41] . However, Tinzaparin treatment of mice at clinically relevant concentration was clearly beneficial over a specific anti-thrombotic treatment, Fondaparinux, strongly suggesting that inhibition of coagulation is not significantly contributing to anti-metastatic activity in a mouse model of experimental metastasis [42] . Here we provide a direct comparison of Tinzaparin with modified heparins (N-acetylated), which has reduced biological activities. Clearly, Tinzaparin has additional beneficial effect over N-acetylated heparin on metastasis, which will be the focus of further investigations.
Our findings describe an important role of integrin VLA-4 engagement on tumour cells by blood components and endothelium during hematogenous spread. However, VLA-4 seems to be also involved in melanoma transmigration through the endothelial cells in vitro. Since integrins are bidirectional signalling molecules, heparin-integrin interaction may also have further consequences beyond the adhesion. Integrins are also involved in the crosstalk with numerous classes of growth factor receptors and cytokine receptors and are able to mediate proangiogenic and proliferative signals to the tumour cells [43] [44] [45] [46] [47] . On contrary, integrins can also initiate pro-survival and pro-tumourigenic as well as pro-apoptotic signals [44, 48, 49] .
The activation of each pathway depends on the ligation status of the integrins by a given cell.
In cells in which most of the integrins are ligated, pro-survival signals were reported whereas pro-apoptotic signals were found in unligated cells [50, 51] . The role of heparin in this complex network will be addressed in future studies.
Concluding, our data introduce VLA-4 as a key player in B16F10 melanoma experimental metastasis, which can efficiently be blocked by the LMWH Tinzaparin, whereby reducing the /100 μL medium) were put into the flow chamber (in some cases after stimulation with 1 mM Mn 2+ ) and allowed to sediment for 5 min. After this period, the flow was started and the adhesion behaviour was monitored over the indicated time range. B16F10 and B16F10 control cells displayed a similar adhesion after Mn . Stimulated platelets showed an augmented adhesion to the cells. This interaction could be abrogated by adding a P-selectin binding mAb (5 µg) or Tinzaparin (500 µg), respectively. A control mAb (5 µg) had no influence on tumour cell platelet interaction. B16F10, B16F10 control, and B16F10-VLA-4kd cells showed nearly an identical adhesion behavior (n.d., no differences between B16F10, B16F10 control cells, and B16F10-VLA-4kd detectable). B) Detached B16F10, B16F10 control, or B16F10-VLA-4kd cells were incubated with TRAP-6 activated (a.p.) and resting platelets (u.p.) (1×10 8 ) for 5 min under gently shaking conditions and then determined by flow cytometry. B16F10 and both clones showed no differences in fluorescence intensity indicating similar platelet interaction capacities. Tinzaparin reduced the tumour cell platelet interaction approximating the behaviour of resting platelets. One representative of three comparable results is shown here. through the tail vein 10 min later. After euthanization, for all three groups metastatic nodules were hardly detectable and tend to zero due to a P-and L-selectin, and VLA-4 inhibition by Tinzaparin and a P-and L-selectin blockade mediated by the N-acetylated heparin derivative. 
